The pharma industry's rep hits absolute. rock. bottom.
After two years of being pilloried by the president and lawmakers for drug pricing, sparking headlines about huge judgments levied for triggering the opioid epidemic (J&J) and hiding manipulated data during an FDA review (Novartis), it may come as no surprise to hear that the industry’s reputation has suffered some.
But it’s worse than that.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.